These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31486857)

  • 21. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
    Calagua C; Russo J; Sun Y; Schaefer R; Lis R; Zhang Z; Mahoney K; Bubley GJ; Loda M; Taplin ME; Balk SP; Ye H
    Clin Cancer Res; 2017 Nov; 23(22):6812-6822. PubMed ID: 28893901
    [No Abstract]   [Full Text] [Related]  

  • 23. PD-L1 Expression in Mastocytosis.
    Williams M; Lidke DS; Hartmann K; George TI
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31086024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.
    Wang Z; Zhao J; Wang G; Zhang F; Zhang Z; Zhang F; Zhang Y; Dong H; Zhao X; Duan J; Bai H; Tian Y; Wan R; Han M; Cao Y; Xiong L; Liu L; Wang S; Cai S; Mok TSK; Wang J
    Cancer Res; 2018 Nov; 78(22):6486-6496. PubMed ID: 30171052
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel.
    Takamochi K; Takahashi F; Suehara Y; Sato E; Kohsaka S; Hayashi T; Kitano S; Uneno T; Kojima S; Takeuchi K; Mano H; Suzuki K
    Lung Cancer; 2017 Aug; 110():26-31. PubMed ID: 28676214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
    Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. About PD-L1 Immunohistochemistry and RNA In Situ Hybridization in Lung Adenocarcinoma.
    Uguen A
    Appl Immunohistochem Mol Morphol; 2019 Jan; 27(1):e9-e10. PubMed ID: 29494400
    [No Abstract]   [Full Text] [Related]  

  • 30. Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.
    Li Z; Joehlin-Price AS; Rhoades J; Ayoola-Adeola M; Miller K; Parwani AV; Backes FJ; Felix AS; Suarez AA
    Int J Gynecol Cancer; 2018 Jan; 28(1):59-68. PubMed ID: 29053481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
    Adam J; Tomasic G; Robert C
    Ann Pathol; 2017 Feb; 37(1):55-60. PubMed ID: 28111041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
    Hata A; Katakami N; Nanjo S; Okuda C; Kaji R; Masago K; Fujita S; Yoshida H; Zama K; Imai Y; Hirata Y
    Lung Cancer; 2017 Sep; 111():182-189. PubMed ID: 28838391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
    Pinto A; Mackrides N; Nadji M
    Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):393-397. PubMed ID: 27801734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 in breast cancer: comparative analysis of 3 different antibodies.
    Karnik T; Kimler BF; Fan F; Tawfik O
    Hum Pathol; 2018 Feb; 72():28-34. PubMed ID: 28843709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
    Fernández A
    Trends Cancer; 2017 Oct; 3(10):675-677. PubMed ID: 28958385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
    Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
    J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical applications of PD-L1 bioassays for cancer immunotherapy.
    Liu D; Wang S; Bindeman W
    J Hematol Oncol; 2017 May; 10(1):110. PubMed ID: 28514966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.